The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
- Author:
Seug Yun YOON
1
;
Jong-Ho WON
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2021;56(S1):S44-S50
- CountryRepublic of Korea
- Language:English
- Abstract: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell malignancies.Chronic inflammation and a dysregulated immune system are central to the pathogenesis and progression of MPNs. Interferon alpha (IFNα) was first used for the treatment of MPNs approximately 40 years ago. It has significant antiviral effects and plays a role in anti-proliferative, pro-apoptotic, and immunomodulatory responses. IFNα is an effective drug that can simultaneously induce significant rates of clinical, hematological, molecular, and histopathological responses, suggesting that the disease may be cured in some patients. However, its frequent dosage and toxicity profile are major barriers to its widespread use. Pegylated IFNα (peg-IFNα), and more recently, ropeginterferon alpha-2b (ropeg-IFNα-2b), are expected to overcome these drawbacks. The objective of this article is to discuss the clinical role of IFNα in Philadelphia-negative MPNs through a review of recent studies. In particular, it is expected that new IFNs, such as peg-IFNα and ropeg-IFNα-2b, with lower rates of discontinuation due to fewer adverse effects, will play important clinical roles.
